Podcasts about Drug delivery

The Power of the Patch: Serguei Melnik Shares How Nutriband Is Disrupting The Drug Delivery BusinessGuestSerguei Melnik Founder & President Nutriband Ticker: NTRBWebsite:https://www.nutriband.com/Bio:Mr. Melnik has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial framework for operations of foreign companies in the U.S.Mr. Melnik advised UNR Holdings, Inc. with regard to the initiation of the trading of its stock in the over-the-counter markets in the U.S., and has provided general advice with respect to the U.S. financial markets for companies located in the U.S. and abroad. From February 2003 to May 2005 he was the Chief Operations Officer and a Board member of Asconi Corporation, Winter Park, Florida, with regard to restructuring the company and listing it on the American Stock Exchange.Mr. Melnik from June 1995 to December 1996 was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,”, Chisinau, Moldova, and prior thereto practiced law in Moldova in various positions. Mr. Melnik is fluent in Russian, Romanian, English and Spanish.Full bio here: https://www.nutriband.com/team-1/serguei-melnik

What does it take to challenge the deadliest brain tumors with sound waves? How do you scale a medtech startup into a multinational clinical company? And what advice can a top neuro-oncology innovator offer to those hoping to follow a similar path? Welcome to Neurocareers: Doing the Impossible! — The podcast where we explore the extraordinary journeys of those advancing the future of neuroscience and neurotechnology. I'm your host, Dr. Milena Korostenskaja. Today we're speaking with Dr. Michael Canney, the Chief Scientific Officer at Carthera, a clinical-stage medtech company revolutionizing brain therapy through therapeutic ultrasound. With over 15 years of experience in MedTech innovation, Dr. Canney specializes in glioblastoma, neurodegenerative diseases, and therapeutic ultrasound drug delivery. He's currently leading the SONOBIRD Phase 3 clinical trial across 40 sites in the U.S. and Europe, pushing the boundaries of what's possible in treating recurrent glioblastoma. Michael's career spans everything from FDA regulatory strategy to high-impact academic collaborations. He's co-authored over 50 peer-reviewed papers in top-tier journals and 14 patent families. But what truly drives him is improving patient outcomes and bringing hope to some of the most challenging areas in brain health. Whether you're curious about clinical trials, neuro-oncology innovations, or carving out your own career in medtech, this conversation is packed with insight and inspiration. Let's dive in! Chapters: 00:00:01 - Revolutionizing Brain Therapy with Ultrasound, Introducing Dr. Michael Canney 00:04:49 - Advancements in Ultrasound for Drug Delivery 00:10:15 - Innovative Ultrasound for Drug Delivery 00:13:49 - Innovative Ultrasound Approach for Tumor Treatment 00:16:02 - Understanding Blood-Brain Barrier Disruption 00:19:28 - Device Overview and Design Features 00:21:32 - Ultrasound Technology for Tumor Treatment 00:24:15 - Device Implantation in Cancer Treatment 00:28:34 - Challenges in Glioblastoma Treatment Trials 00:31:46 - Dr. Michael Canney's Journey into Ultrasound Research 00:36:15 - Starting a Postdoc Journey 00:39:20 - Career Development in Neuroscience 00:43:31 - Building a Startup Team 00:47:38 - Hiring for Clinical Application Specialists 00:52:16 - Growth of Careers in Neurotechnology 00:54:26 - Using AI in Clinical Trials 00:57:13 - Challenges in Medical Device Approval 00:59:41 - Overcoming Challenges in Medical Innovations 01:02:20 - Clinical Trials and Company Information About the Podcast Guest: Michael Canney, Ph.D., is Chief Scientific Officer at Carthera, a clinical-stage medtech company advancing brain therapy through innovative ultrasound-based devices. A co-author of more than 50 peer-reviewed articles, he specializes in neuro-oncology, glioblastoma and neurodegenerative diseases. At Carthera, he is responsible for leading scientific collaborations with academic institutions, organizing U.S. clinical trials and more. Connect with Dr. Canney on LinkedIn: https://www.linkedin.com/in/michael-canney-ph-d-42457b5/ Learn more about Carthera: https://carthera.eu/ Get familiar with the Sonobird clinical trial: https://sonobird.eu/ About the Podcast Host: The Neurocareers podcast is brought to you by The Institute of Neuroapproaches (https://www.neuroapproaches.org/) and its founder, Milena Korostenskaja, Ph.D. (Dr. K), a career coach for people in neuroscience and neurotechnologies. As a professional coach with a background in neurotech and Brain-Computer Interfaces, Dr. K understands the unique challenges and opportunities job applicants face in this field and can provide personalized coaching and support to help you succeed. Here's what you'll get with one-on-one coaching sessions from Dr. K: Identification and pursuit of career goals Guidance on job search strategies, resume, and cover letter development Neurotech / neuroscience job interview preparation and practice Networking strategies to connect with professionals in the field of neuroscience and neurotechnologies Ongoing support and guidance to help you stay on track and achieve your goals You can always schedule a free neurocareer consultation/coaching session with Dr. K at https://neuroapproaches.as.me/free-neurocareer-consultation Subscribe to our Nerocareers Newsletter to stay on top of all our cool neurocareers news at updates https://www.neuroapproaches.org/neurocareers-news  

What can surface-enhanced Raman spectroscopy tell us about the presence of novichok? How can we improve our understanding of how asteroids respond to the tactics we may need to deploy for planetary defence? And as incidences of wildfires grow, how can Europe's response be more effective? Listen on to hear the answers to these and many other key questions. Joining us for this episode are: Patrick Michel, a director of research at the French National Centre for Scientific Research in the Côte d'Azur Observatory in Nice. He is involved in space missions to asteroids, for both science and planetary defence purposes and is the principal investigator of the European Space Agency's Hera mission, which contributes to the first asteroid deflection test through NASA's DART mission.  Emilio Chuvieco, professor of Geography and director of the Environmental Ethics chair at the University of Alcalá, Spain, and his main interest is the use of Earth Observation data to monitor environmental problems, particularly forest fires. Tomas Rindzevicius, a senior researcher in the Department of Health Technology, Drug Delivery and Sensing, at the Technical University of Denmark, who focuses on the application of nanomaterials for sensing applications to detect trace amounts of explosives, toxic industrial chemicals and chemical warfare agents.  

Lucy Sheldon and Clare Beddoes from Cambridge Design Partnership explain how to develop clear instructions for medical devices, and what Apple can teach us about making products so intuitive we don't need instructions at all. And how do LEGO make instructions part of the act of play itself? When you walk into reception at Cambridge Design Partnership, you see lots of intriguing case studies on display – from heart catheters to smart pills to nasal swabs. As an innovation consultancy, it's critical that people can actually use the medical devices they develop. Which is where clear instructions come in. Lucy Sheldon is a Human Factors Engineer, focusing on good interaction design – helping people be at one with the technology they're using – not battling against it. Clare Beddoes heads up Drug Delivery, thinking about the needs of the patient and medical teams. She works closely with Lucy's team to make sure the drugs can be used safely, minimising risk in a very risk averse sector. We talk about the importance of sound and visuals in helping people use devices properly – and how they consider the emotional state of the end user, whether it's someone using an Epi-Pen in a panic - or nervously taking a pregnancy test in the bathroom. And we take a break in the middle for playtime! Looking at LEGO and instructions aren't just functional, they're all part of the fun too. Useful links Connect with our guests on LinkedIn Clare Beddoes: https://www.linkedin.com/in/clare-beddoes-661b2913 Lucy Sheldon: https://www.linkedin.com/in/lucysheldon Cambridge Design Partnership: https://www.linkedin.com/company/cambridge-design-partnership --- Sookio podcast page: https://www.sookio.com/podcast Produced by Rob Birnie at Made By DBM: https://madebydbm.com Links recorded at Cranes Nest podcast studio in Cambridge: https://www.thecranenest.co.uk/ Hosted on Acast. See acast.com/privacy for more information.

What if you could take lower doses of medication with better results and fewer side effects? In this episode of Healthy Choices, Dr. Richard Horowitz joins Ray Solano of PD Labs to reveal a breakthrough in drug delivery that's changing the game. Discover how PD Labs' cutting-edge nanosphere technology enhances absorption, improves efficacy, and minimizes side effects—making treatments like methylene blue and low-dose naltrexone (LDN) safer and more effective. Plus, get an inside look at upcoming clinical trials, including groundbreaking research on Lyme disease treatment. If you're interested in the future of medicine, this is a must-listen! ---- In this episode of Healthy Choices, I dive into an exciting breakthrough in drug delivery with Dr. Richard Horowitz. We're talking about PD Labs' patented nanosphere technology—a game-changer that boosts drug absorption, minimizes side effects, and enhances treatments for Lyme disease, testosterone therapy, and low-dose naltrexone (LDN). Plus, we'll share the latest on upcoming clinical trials and cutting-edge research that could redefine the future of medicine. Don't miss this fascinating discussion on the next evolution of personalized healthcare! ---- Dr. Richard Horowitz is a renowned Lyme disease specialist and co-host of the Doctor Talk Healing Lyme Summit 2.0. He is leading research on innovative treatments, including the use of methylene blue and dapsone in Lyme disease protocols. ---- https://www.linkedin.com/in/richard-horowitz-b4634012/ ---- PODCAST Thank you for listening. Please subscribe and share. This podcast is produced by DrTalks.com drtalks.com/podcast-service/

Discover how ampoule(ampule) drug delivery systems could revolutionize the pharmaceutical industry in this eye-opening video. Learn about the potential impact of this innovative technology on drug administration and patient care.In this episode of 'Let's Combinate Drugs and Devices,' host Subhi Saadeh is joined by Eric Suglalski, Founder and CTO of Archimedic, to discuss the often-overlooked role of ampules in drug delivery. Eric highlights the stability and contamination resistance benefits of ampules, despite the industry's shift towards vials and pre-filled syringes. He elaborates on the time and cost factors that make transitioning to pre-filled syringes challenging for pharmaceutical companies. The discussion also covers Eric's work on the Ampule Filled Syringe (AFS) system, which aims to combine the usability of pre-filled syringes with the stability of ampules. They delve into the historical context of ampules, global usage patterns, and the hurdles faced in implementing ampule-based technologies. Eric invites interested pharma companies to explore potential collaborations with Ampulous.00:00 Introduction and Guest Welcome00:17 The Overlooked Potential of Ampoules02:11 Challenges with Vials and Prefilled Syringes05:01 The Cost and Time Barrier to Prefilled Syringes08:29 Introducing Ampulous: A New Solution10:36 Technical Details of Ampule Filled Syringes14:39 Historical Context and Global Use of Ampoules16:38 Addressing Concerns and Resistance18:01 Human Factors and Usability19:44 Conclusion and Contact InformationEric Sugalski is the Founder and CTO of Archimedic, a contract design and development organization (CDMO) specializing in drug delivery devices and combination products. With over 25 years of experience in medical device development, he has worked extensively on early-stage concept development, human factors engineering, and commercialization strategies. His work spans life-support systems, remote monitoring technologies, and drug delivery devices, with a focus on balancing technical innovation with market viability. In addition to leading Archimedic, he teaches courses on product development, regulatory strategy, and entrepreneurship at institutions like MIT, the University of Pennsylvania, and West Chester University, helping to bridge the gap between engineering education and industry application. Subhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee.For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

As we gain a better understanding of how misfiring brain circuits lead to mental health conditions, we'd like to be able to go in and nudge those circuits back into balance. But this is hard — literally — because the brain is encased in this thick bony skull. Plus, often the problem you want to target is buried deep in the middle of a maze of delicate brain tissue you need to preserve.Today we're going to be talking with neuroscientists who aim to solve this problem with sound. And not just any sound: ultrasound.Kim Butts Pauly and Raag Airan from the Stanford Department of Radiology are developing ultrasound technology in a couple of different ways to essentially reach into the brain to treat brain disorders that are otherwise hard to access. These uses of ultrasound haven't yet reached the clinic, but could be entering clinical testing in people in the next few years. Mentioned on the ShowMeet the 2025 Neurosciences Postdoctoral Scholars (Wu Tsai Neuro, 2025)Butts Pauly LabAiran LabNon-invasive brain stimulation opens new ways to study and treat the brain (Wu Tsai Neuro, 2025)Advancing Brain Resilience: 2024 Catalyst and Pilot Grant Awards (Knight Initiative for Brain Resilience, 2024)Researchers find response to ketamine depends on opioid pathways, but varies by sex (Stanford Medicine)A New Focused Ultrasound Neuromodulation System for Preclinical Brain Research (Focused Ultrasound Foundation, 2024)Translating Neuroscience Advances into Real World Uses (Wu Tsai Neuro, 2023)Get in touchWe want to hear from your neurons! Email us at at neuronspodcast@stanford.edu if you'd be willing to help out with some listener research, and we'll be in touch with some follow-up questions.Episode CreditsThis episode was produced by Michael Osborne at 14th Street Studios, with production assistance by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute and supported in part by the Knight Initiative for Brain Resilience at Wu Tsai NeuSend us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

In this episode of The Rob & Jai Show, Michael O'Rourke, CEO of Re-Vana Therapeutics, joins Dr. Rob Rothman and Dr. Jai Parekh to explore the next-generation of sustained drug delivery in ophthalmology. With millions of intravitreal injections administered annually for retinal diseases like AMD, the need for longer-lasting, more effective treatments has never been greater.O'Rourke explains how Re-Vana's proprietary hydrogel-based technologies are setting a new standard for biodegradable, sustained-release drug implants—offering six to twelve months of therapeutic coverage without the need for surgery. The discussion covers:

Michael Demurjian is Chairman and CEO of Aspargo Labs, a drug development company focused on improving drug delivery through suspension-based formulation and smart device technology. Traditional pill-based drug delivery has significant limitations, with poor absorption rates and difficulties swallowing for many patients. The company's initial focus is on an oral spray formulation of sildenafil to treat erectile dysfunction that has shown rapid absorption. Suspension technology can be applied to reformulate many prescription and over-the-counter drugs to improve drug delivery, adherence, the onset of action, and user experience. Michael explains, "Here at Aspargo we have a proprietary technology, both in the suspension and in how we coat it, so that we can mask the taste of the drug itself. And so I know you're going to probably go down the path of our first drug to market, and I'll answer the next question, but masking is key because there are two things that happen with the masking. One is you make it more of a pleasant experience. People are more willing to adhere and comply than administering the drugs. If you don't, people are going to say, my goodness, that tasted horrible, and I'm not going to do that again. Or they're going to be resistant in particular children, they won't do it."  "Well, 30 years in the drug development business, and I will tell you, you bring an ED product to market where you're showing a five-minute absorption time, it captures a lot of people's attention. So we've been very well received. Our first drug to market is an oral spray, sildenafil, which is the active ingredient in Viagra. And what we've shown is a five-minute absorption time. So, it has a lovely peppermint flavor. Now, here's the key there. Sildenafil is extremely bitter. It's one of the top 20 most bitter drugs that is manufactured. Our taste is peppermint. Through the proprietary technology that we have, we've successfully bonded the flavor agents right to the molecule without damaging it. I'll tell you, it's an interesting experience. Typically, it's the medical community. But when you're looking at a drug like Sildenafil, it's a consumer experience as well." "You have to remind yourself the efficiency of absorption is critical. We look at patients, particularly in oncology, where we know that if they miss a dose of a medicine, cancers rapidly reproduce. So, missing one dose can set a patient back. What we look at and focus on is two things. One is our device to remind patients to dose their medicine. And if they forget that their physician, the physician assistant, or the office manager can intervene and text or call them saying your device just said you didn't dose. That's key." #AspargoLabs #DrugDelivery #ED #ErectileDysfunction #Sildenafil #DrugAdherence #MedTech aspargolabs.com Listen to the podcast here

Michael Demurjian is Chairman and CEO of Aspargo Labs, a drug development company focused on improving drug delivery through suspension-based formulation and smart device technology. Traditional pill-based drug delivery has significant limitations, with poor absorption rates and difficulties swallowing for many patients. The company's initial focus is on an oral spray formulation of sildenafil to treat erectile dysfunction that has shown rapid absorption. Suspension technology can be applied to reformulate many prescription and over-the-counter drugs to improve drug delivery, adherence, the onset of action, and user experience. Michael explains, "Here at Aspargo we have a proprietary technology, both in the suspension and in how we coat it, so that we can mask the taste of the drug itself. And so I know you're going to probably go down the path of our first drug to market, and I'll answer the next question, but masking is key because there are two things that happen with the masking. One is you make it more of a pleasant experience. People are more willing to adhere and comply than administering the drugs. If you don't, people are going to say, my goodness, that tasted horrible, and I'm not going to do that again. Or they're going to be resistant in particular children, they won't do it."  "Well, 30 years in the drug development business, and I will tell you, you bring an ED product to market where you're showing a five-minute absorption time, it captures a lot of people's attention. So we've been very well received. Our first drug to market is an oral spray, sildenafil, which is the active ingredient in Viagra. And what we've shown is a five-minute absorption time. So, it has a lovely peppermint flavor. Now, here's the key there. Sildenafil is extremely bitter. It's one of the top 20 most bitter drugs that is manufactured. Our taste is peppermint. Through the proprietary technology that we have, we've successfully bonded the flavor agents right to the molecule without damaging it. I'll tell you, it's an interesting experience. Typically, it's the medical community. But when you're looking at a drug like Sildenafil, it's a consumer experience as well." "You have to remind yourself the efficiency of absorption is critical. We look at patients, particularly in oncology, where we know that if they miss a dose of a medicine, cancers rapidly reproduce. So, missing one dose can set a patient back. What we look at and focus on is two things. One is our device to remind patients to dose their medicine. And if they forget that their physician, the physician assistant, or the office manager can intervene and text or call them saying your device just said you didn't dose. That's key." #AspargoLabs #DrugDelivery #ED #ErectileDysfunction #Sildenafil #DrugAdherence #MedTech aspargolabs.com Download the transcript here

In this episode of the Med-Tech Talent Lab podcast, host Mitch Robbins interviews Jeff Gensler, the Vice President of Quality at Kindeva Drug Delivery, about the innovative 'Frame by Frame' approach to manufacturing processes. Jeff's background spans over 20+ years of experience in Med-Tech Regulatory & Quality having held prominent positions with companies like Dentsply, Zimmer Biomet, and others prior to joining Kindeva. Jeff explains how this method revolutionizes process development by breaking down procedures into micro-steps and utilizing AI for risk assessment and training. The conversation covers the origins of this approach, its implementation in aseptic processing, and the significant time and cost savings it offers. Jeff also discusses the impact on roles within the industry, the feedback received from peers, and his personal journey in quality assurance. Tune in to learn about this revolutionary way of developing & implementing processes. Your views & approach will be forever changed....for the better!Jeff Gensler on LinkedIn:https://www.linkedin.com/in/jeff-gensler-67a54a1a/Kindeva Drug Delivery on the web:https://www.kindevadd.com/

In this episode of Let's Combinate, host Subhi Saadeh dives into the world of digital transformation in healthcare with Dr. Timothy Aungst, a visionary pharmacist and digital health expert. Dr. Aungst breaks down digital therapeutics, smart drug delivery systems, and wearable technology. He elaborates on the nuances of digitalization, digital transformation, and how these concepts are reshaping the pharmaceutical and healthcare industries. The discussion also touches on the evolving role of pharmacists in a tech-driven healthcare landscape, the impact of AI, and the regulatory challenges in adopting new technologies. 00:00 Introduction to Digital Apothecary with Dr. Timothy Ongst 01:00 Understanding Digital Transformation in Healthcare 03:11 The Evolution of Digital Health and Its Impact 08:23 Future of Healthcare: Expectations and Innovations 13:03 Challenges and Strategies in Pharma's Digital Transformation 20:46 The Role of Digital Tools in Drug Delivery and Adherence 21:19 Challenges of Digital Integration in Healthcare 22:14 Pharmacist's Perspective on Drug Line Therapy 24:04 Clinical and Payer Considerations 25:33 Digital Transformation in Medication Efficacy 30:36 Regulatory Challenges and Bias in Healthcare 36:38 The Role of AI in Digital Health 39:48 Closing Thoughts and Future Outlook Dr. Timothy Aungst is a leading expert in digital health and pharmacy, widely recognized for his work in advancing digital therapeutics, medication adherence technologies, and the integration of health apps into clinical practice. As the voice behind The Digital Apothecary, Dr. Aungst bridges the gap between emerging digital health innovations and the pharmaceutical landscape. His insights provide valuable guidance for healthcare professionals navigating the rapidly evolving intersection of technology and medicine. Subhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations and R&D he's worked in Large Medical Device/Pharma organizations to support the development and launch of Hardware Devices, Disposable Devices, and Combination Products for Vaccines, Generics, and Biologics. Subhi serves currently as the International Committee Chair for the Combination Products Coalition(CPC) and as a member of ASTM Committee E55 and also served as a committee member on AAMI's Combination Products Committee. For questions, inquiries or suggestions please reach out at letscombinate.com or on the show's LinkedIn Page.

Data drives MedTech growth, from the leanest startup to the world's most valuable pharmaceutical company. In Episode #36 of the MedTech Speed to Data Podcast, Key Tech's Andy Rogers discusses data-driven trends in medical technology with Anand Subramony, Eli Lilly's Vice President of Drug Delivery, Device, Connected Solutions & Innovation.Need to know·       Quarter-century perspective — After getting his PhD in chemistry and materials science from Purdue University, Subramony spent the next twenty-five years developing novel medical technologies for firms like Johnson & Johnson, Novartis, and AstraZeneca.·       Cutting-edge combination product development — Now at Eli Lilly, Subramony's team is responsible for combination product development, from early development through commercial development, for new delivery dosage forms.The nitty-grittySubramony drew upon his career-spanning perspective to discuss significant data-driven trends that impact the entire industry, not just Eli Lilly.One topic he raised in his conversation with Andy was using data to monitor disease state progression. Already an important element of fields like neurology and oncology, extensive data collection will become essential to a wider range of treatments. For many conditions, Subramony explains, disease state is a binary evaluation.“You can really understand disease state progression using digital biomarkers and collecting data throughout [the treatment],” Subramony said. “I think these are areas where there is a lot of potential.”Another data-driven trend Subramony discusses is the adoption of direct delivery therapies. When treating tumors and other conditions, off-target toxicity can cause unfortunate side effects. Genetic medicines, such as mRNA therapies, can target the cell surface, protect the cargo, and prevent endosomal escape.“It's going to disrupt the way we look at drug delivery from macroscopic pen auto-injector deliveries to microscopic, targeted deliveries where you need to take the therapeutic moiety into the site of action,” Subramony said.Data that made the difference:This episode's wide-ranging conversation covered many additional topics of interest to the MedTech community, including:GLP-1 treatments are “really transformative” for individual patients who can afford them. However, bringing costs down will depend on data demonstrating how lower obesity and healthier lifestyles reduce the overall burden on the healthcare system.For sensors and connected devices to go beyond “bells and whistles,” the industry must drive value from how we use that data. Relating compliance to efficacy, for example, makes moving patients from less effective to more effective therapies easier and faster.Continuous monitoring can improve healthcare outcomes but requires new data management practices to govern how much data is collected, who is collecting and viewing the data, and what are the privacy rules protecting patients. 

This podcast features a panel discussion on desgining and developing drug delivery and devices for LMICs with representatives from Gilead Sciences, the Bill & Melinda Gates Foundation, ApiJect and AbbVie From the 2024 PODD: Partnership Opportunities in Drug Delivery. The panelists discuss unique and compelling challenges of the last mile for LMICs, the role of pharma and medtech in the evolution of LMIC drug development, trends in the space, case studies of successful products and how to better consider cultural differences between LMICs and more developed markets. To learn more about the PODD conference, please visit PODDConference.com.

Science and Eschatology: Tower of Babel Tech: WEF (AI, Quantum Computing and Drug Delivery) AntiChrist Tech. Source material: WEF/HEALTH AND HEALTHCARE SYSTEMSHow the AI and quantum revolution will transform drug discovery and medical diagnostics. Jan 2024.World Economic Forum (Switzerland).To support the [Show] and its [Research] with Donations, please send all funds and gifts to :$aigner2019 (cashapp) or https://www.paypal.me/Aigner2019 or Zelle (1-617-821-3168). Shalom Aleikhem.

In this episode, we chat with Professor Kathryn (Katie) Whitehead, a renowned chemical engineer and Professor at Carnegie Mellon University. We explore Katie's path to a career in science, her breakthroughs and innovative ideas in drug delivery, and her dedication to improving science communication.Professor Kathryn Whitehead discusses the challenges in drug delivery, including in maternal health, an underserved area of research. In 2018 Katie received the NIH Directors New Innovator Award for an idea to use breastmilk cells for infant therapies and has since made some key discoveries towards this goal.The episode also focuses on discussions on lipid nanoparticles (LNPs) and their emergence as vehicles for delivering RNA. Katie discusses how their use extends further than for mRNA vaccines and opens promising avenues for the treatment of chronic genetic conditions.Key Takeaways Katie explains the process behind her innovative idea that was awarded the NIH Director's New Innovator Award for a project titled “Fate, Function and Genetic Engineering of Breast Milk Cells for Infant Therapy”. Lipid Nanoparticles (LNPs) are poised to revolutionize drug delivery, showing promise far beyond their role in COVID-19 vaccines. Effective science communication, exemplified by Katie's viral TED talk, is crucial in demystifying complex scientific concepts for the broader public.Resources Professor Kathryn Whitehead's lab website: Whitehead Lab - Carnegie Mellon (cmu.edu) TED Talk by Kathryn A. Whitehead on lipid nanoparticles: Kathryn A. Whitehead: The tiny balls of fat that could revolutionize medicine | TED Talk

As viruses evolve to resist vaccines and therapeutics, new targeted approaches to deliver broad-spectrum antivirals are needed. In this podcast, Anil Diwan, President and Executive Chairman of NanoViricides Incorporated, explains some of the shortcomings of the current model of antiviral drug development and how NanoViricides developed a nanotechnology with a different approach to develop and deliver antiviral drugs. Anil also presents an overview of the scientific and clinical development of NanoViricides lead program, NV-387 as well as potential applications in different indications.  For more information about NanoViricides Incorporated, visit NanoViricides.com.  For more information about the annual  PODD drug delivery conference, please visit Drug-Delivery.org.

 In this compelling episode of Research Renaissance, host Deborah Westphal sits down with Afreen Allam, the CEO and founder of SiNON Nano Sciences and a 2023 Termeer Fellow. Afreen shares her journey from aspiring medical student to biotech entrepreneur, discussing her groundbreaking work in drug delivery for neurological diseases. The conversation delves into the challenges and triumphs of developing a platform that can cross the blood-brain barrier, offering hope for the treatment of diseases like Cancer, Alzheimer's, Parkinson's, and brain tumors.Key Discussion Points:SiNON Nano Sciences' Mission: Afreen explains the innovative approach her company takes to target drug delivery across the blood-brain barrier, using a carbon-based nanoparticle that can safely and effectively transport medications to the brain.Personal Journey: Afreen reflects on her transition from a pre-medical student to a biotech entrepreneur, sharing how her experiences volunteering at the Duke Cancer Center inspired her to pursue research that could improve the quality of life for patients.Challenges in Drug Delivery: The discussion covers the unique difficulties of delivering drugs to the brain, the limitations of current technologies, and how SiNON Nano Sciences aims to overcome these obstacles with their platform.The Importance of Support and Mentorship: Afreen highlights the significance of mentorship and support systems, particularly her experience as a 2023 Termeer Fellow, which provided her with valuable resources, connections, and guidance.The Future of Drug Delivery: Afreen discusses the potential partnerships with pharmaceutical companies and the importance of collaboration in advancing treatments for neurological diseases.Guest Bio: Afreen Allam is the CEO and founder of SiNON Nano Sciences, a biotech startup focused on developing a platform for targeted drug delivery to the brain. A 2023 Termeer Fellow, Afreen is passionate about improving patient outcomes and has a background in biochemistry, microbiology, and business.Call to Action: Subscribe to Research Renaissance for more episodes featuring trailblazers in brain science and healthcare innovation. Visit tofflertrust.org for additional resources and updates. Until then, onward and upward!To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

On this episode, I was joined by Laxman Halleppanavar, Head of Portfolio Strategy and Management at Credence MedSystems, Inc. On this episode, Laxman, highlights the differences in regulatory oversight and risk management between medical devices and pharmaceuticals, the trend towards home administration of drugs, sustainability goals, and the challenges posed by longer-acting drugs, higher viscosities, and large injection volumes. Laxman also discusses his transition from large corporations to startups and the multifaceted nature of scaling up projects. 00:00 Introduction to the Combinate Podcast 00:56 Understanding the Intersection of Medical and Pharmaceutical Industries 02:56 Challenges in Medical Devices and Pharmaceuticals 03:22 Governance and Risk Management in Healthcare 08:13 Transitioning from Big Pharma to Startups 15:46 Trends in Injection Delivery Systems 28:38 Challenges in Home Administration and Sustainability 31:07 Scaling Up in the Pharmaceutical Industry 32:47 Conclusion and Contact Information Laxman Halleppanavar is currently the Head of Portfolio Strategy and Management at Credence MedSystems, leading the Injectable Device Portfolio Strategy and Management team for internal and external customer endeavors. Previously, Mr Halleppanavar was the Director - PharmSci Technical Team Lead at Pfizer. He came to Pfizer upon its acquisition of Hospira where Mr Halleppanavar was responsible for combination product development from early-stage development to manufacturing scale up leading to commercial launch. Prior to Pfizer, Mr Halleppanavar was the Program Manager at GE Healthcare responsible for development, manufacturing, and commercialization of multiple medical device/patient monitoring platforms namely, patient worn devices, blood pressure cuffs, bedside monitoring devices, networked central & remote monitoring stations.

Unleashing Innovation in Pet Health with John Lai of PetVivo HoldingsI'm thrilled to share the latest episode of our podcast, featuring an insightful interview with John, the President and CEO of PetVivo Holdings. If you're passionate about innovative medical technology and the future of pet health, this episode is a must-listen!Here are some key takeaways and intriguing insights from our conversation:

Kamalesh Rao is the founder and CEO of Lifescient.  Lifescient was established by Kamalesh, who has twenty-five years of experience in Pharmaceutical development. He played a pivotal role in the team that successfully created a sustained-release injectable to alleviate symptoms of opioid withdrawal in humans.  Renee Sera is the Chief Administrative Officer and one of the founding investors of Lifescient.  She is a small business owner, real estate developer, and an angel investor.   Learn more about Lifescient at https://lifescient.com/ Support Lifescient's crowdfunding campaign at: https://wefunder.com/lifescient Follow on LinkedIn:  https://www.linkedin.com/company/lifescient-inc Contact with comments or questions: kamalesh@lifescient.com Contact Julie at jacappeldvm@gmail.com https://Theveterinarylifecoach.com           

To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.

Christine Allen, professor at the University of Toronto's Leslie Dan Faculty of Pharmacy, discusses how new drug-delivery models are transforming cancer treatment, her experiences with commercialization and entrepreneurship, and the upsides of carrying out her work at the University of Toronto.This episode was made possible by the University of Toronto and the generosity of listeners like you. Donate today.The Hub Dialogues features The Hub's editor-at-large, Sean Speer, in conversation with leading entrepreneurs, policymakers, scholars, and thinkers on the issues and challenges that will shape Canada's future at home and abroad.If you like what you are hearing on Hub Dialogues consider subscribing to The Hub's free weekly email newsletter featuring our insights and analysis on key public policy issues. Sign up here: https://thehub.ca/join/. Hosted on Acast. See acast.com/privacy for more information.

On this episode, I was joined by Maysaa Attar, Senior Vice President of R&D at Bausch + Lomb. On this episode, Maysaa discusses: 00:00 Welcome to Episode 150! 03:00 Challenges and Innovations in Ocular Drug Delivery 09:30 Understanding Intravitreal Injections 13:26 Regulatory Considerations for Ocular Products 20:48 Innovations in Glaucoma Treatment 29:18 The Personal Impact of Vision Loss 35:40 Book Recommendations and Final Thoughts Maysaa Attar is the Senior Vice President of R&D at Bausch & Lomb, leading global pharmaceutical and consumer product research and development. She has held prominent leadership positions at Abbvie and Allergan and holds a PhD in Pharmaceutical Sciences from the University of Southern California (USC), where she also serves as a professor.

Bioconjugation of antibodies to drugs via chemical linkers is how antibody drug conjugates (ADCs) are made. We're joined by Matt Giese, Senior Scientist at Vector Laboratories, who talks us through the complex chemistry options and biodesign considerations that have to be considered and balanced when making a successful ADC.How does one build the skillset to work in biodesign of ADCs you might ask? Well, Matt's career path might not provide a clearcut roadmap like you might hope. That's because Matt started his career as an auto mechanic, moved into art, went back to auto mechanics, worked as baggage handler and as a construction worker, all before ever finding chemistry. If you think that's a convoluted path, just wait to hear about his academic and professional work journeys.  You'll revel in following this journey, and in the lessons and diverse skills learned along the way. Join us to hear it yourself, from who might just be the most interesting man in chemistry!Related episodes:Season 5, Ep.7: The life-altering impact of one chemist's sabbaticalSeason 2, Ep.1: Chemistry: a modern American dreamSeason 3, Ep.5: On the COVID pill and other process chemistry tales Bonus content!Access bonus content curated by this episode's guest by visiting www.thermofisher.com/chemistry-podcast for links to recent publications, podcasts, books, videos and more.View the video of this episode on www.thermofisher.com/chemistry-podcast. A free thank you gift for our listeners! Request your free Bringing Chemistry to Life t-shirt on our episode website.Use Podcast Code: LabRatsRul3 in July or OchemRcks in August. We read every email so please share your questions and feedback with us! Email helloBCTL@thermofisher.com

Before bringing a new device into your practice, it's prudent to understand the science behind, indications for, and insurance coverage of that device. In this episode, Dr. Rajiv Pandit, comprehensive otolaryngologist at Dallas ENT Head & Neck Surgery Center, joins BackTable to discuss his success treating sinusitis with drug-eluting stents. --- CHECK OUT OUR SPONSOR Medtronic ENT Propel Implants https://www.medtronic.com/us-en/healthcare-professionals/medical-specialties/ear-nose-throat.html?cmpid=Vanity_URL_MIX_medtronicent-com_202212_US_EN_NS_ENT_FY23 --- SYNPOSIS First, Dr. Pandit shares the benefits of localized drug delivery, including fewer systemic steroid effects and improved compliance. He shares his experience deploying Propel and SINUVA stents to treat sinusitis. Then, Dr. Pandit shares his workflow for treating sinusitis, including patient education, anesthesia protocols, stent placement, and billing. The episode wraps with his tips on incorporating a new device into your practice. --- TIMESTAMPS 00:00 - Introduction 02:44 - Dr. Rajiv Pandit's Path to Treating Sinusitis in Private Practice 04:31 - Understanding Local Drug Delivery for Sinus Disease 06:17 - The Evolution of Propel & Sinuva Sinus Stents 18:33 - Contraindications & Post-Op Protocols 32:35 - Understanding Insurance Coverage & Preauthorization 37:47 - Patient Education & Long-Term Treatment Plans 48:10 - Anesthetic Protocols for In-Office Sinonasal Procedures 54:48 - Bringing Drug-Eluting Sinus Stents to Your Practice --- RESOURCES Dr. Pandit's Dallas ENT Profile: https://www.dallasent.com/providers/rajiv-pandit Dallas ENT Instagram: https://www.instagram.com/dallas.ent/embed/ Dr. Pandit's Email: drpandit@dallasent.com

We love to hear from our listeners. Send us a message. Syncromune's Sync-T solid tumor therapeutic platform is, in a word, complex. The company's three phase 1 programs combine T-cell science with a proprietary drug delivery device to target solid tumors, specifically metastatic breast, non-small-cell lung, and castrate-resistant prostate cancers. But, while orchestrating a successful drug/device combination therapy presents unique regulatory challenges and requires a diverse array of in-house skillsets, President and CEO Eamon Hobbs is confident. He's done this before, and Syncromune's lead candidate has just been fast-tracked by the FDA. On this episode of the Business of Biotech, Hobbs shares his perspectives on bringing novel drug/device combination therapies to market, and reflects on a career dedicated to the drug delivery craft and demonstrated by his leadership at Antares Pharma, Delcath Systems, AngioDynamics. Register for Bioprocess Online's Bio Expo Live, being held July 30th through August 1st . This inaugural expo is a fantastic opportunity for biopharma companies and contract manufacturers to evaluate the latest and greatest from the comfort of your desktop or mobile device. Conveniently, we've broken down the lineup into Upstream Solutions July 30th, Downstream Solutions July 31st, and Quality, Analytical, and Data Solutions August 1st. It's absolutely free to register for this series of short, digestible, and interactive sessions -- just hit the links above to register for Bio Expo Live today!

On this episode, I was joined by Alan Stevens and Rumi Young who walk through the contents of the FDA Draft Essential Drug Delivery Outputs for Devices Intended toDeliver Drugs and Biological Products Guidance for Industry. Industry Comments are DUE 9/29/2024. Alan Stevens is the Global Head of Complex Devices and Drug Delivery Systems at AbbVie within the RA Emerging Technologies, Devices and Combination Products team. Prior to joining AbbVie, Alan spent 20 years at the FDA/CDRH leading premarket review and policy development for drug delivery devices and combination products. Rumi Young, Meng, RAC is the Director of Regulatory Policy at Novo Nordisk. Rumi joined Industry from FDA where she spent four years in CDRH's Division of Drug Delivery, General Hospital and Human Factors. As Acting Assistant Director for Injection Devices, her team was responsible for the approval of drug delivery injection devices and combination products such as syringes, auto injectors, pen injectors, on-body injectors and smart connected devices. Prior to FDA Rumi worked at Genentech and AstraZeneca for eight years in combination product development. Rumi has both a Bachelors in Chemistry and Chemical Biology and Masters in Engineering in Material Science from Cornell University.

Dr. Ankush Bhatia interviews Dr. Keaton Piper about his and his team's manuscript, entitled "Consensus Review on Strategies to Improve Delivery Across the BBB Including Focused Ultrasound", published online in Neuro-Oncology in May 2024 Read Paper

Explore the entrepreneurial path of John Lewis with us – from Canadian income tax consultant to biotech exec, John has carried a passion for building teams and putting innovation to work to solve some big problems in drug delivery.

Show Notes: Graphene Quantum Dots (GQDs) for BIO-IMAGING and Drug Delivery Applications: A Review and Deconstruction of the Lie that Graphene as pertains to COVID related biomedical applications was a “ Nonsensical Conspiracy Theory”. Graphene has been used and will continue to be used as a nanotech drug delivery mechanism and apparatus for the foreseeable future. Please support the [Show] and its [Research] with Donations, please send all funds and gifts to :$aigner2019 (cashapp) or https://www.paypal.me/Aigner2019 or Zelle (1-617-821-3168).}

CEO Andrew Webb of Extruded Pharmaceuticals discusses Amur Minerals reverse takeover, which leads to an exciting transformation into drug delivery. Amur is currently classified as an AIM Rule 15 cash shell. It proposes to acquire 100 per cent. of EPL by way of an RTO under AIM Rule 14. Amur has called a general meeting of the Company in order to approve the proposed RTO, approve a change of name to CRISM Therapeutics, and approve a share consolidation of 1 new ordinary share for every 160 existing ordinary shares. EPL is a UK-based pharmaceutical company which was founded in March 2016. EPL has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. ChemoSeed®, EPL's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This ensures that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating high grade glioma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective. ChemoSeed addresses a significant, unmet medical need in the treatment of glioblastoma and high grade glioma. There are no current cures and present treatments merely seek to simply extend life, often by just a few months, with serious adverse side effects. Each ChemoSeed consist of a chemotherapeutic agent (irinotecan) and a bioresorbable polymer, both of which have been previously administered to the brain with no toxicity issues. This, combined with the target markets for ChemoSeed being unmet medical needs, means EPL could potentially receive conditional marketing authorisation in the UK on the back of positive Phase II clinical trial data. This authorisation could be received as early as 2028, therefore reducing the time and cost to commercialisation of irinotecan loaded ChemoSeeds for glioblastoma and high-grade glioma treatment. ------------ Some of the benefits of being a member of the SharePicker Investment Club:  *** The UK's only MicroCap League: 100's of potential small cap investment ideas analysed and scored in relation to their growth, value, health, efficiency, momentum & potential.  *** Free Investment Book: How to become a MicroCap Millionaire (3 Step Strategy) by Justin Waite.  *** Weekly Live Webinar: Justin analyses potential investment ideas, fundamentally & technically. He discusses his own holdings together with portfolio management and other aspects of investing.  *** Blog: Justin will post a blog when he invests in a new company, on the day he invests.  *** My Watchlist: This is a list of companies Justin think's may have some decent investment potential.  *** Stock Requests: Members suggest stocks to be analysed on the webinar.  *** Company Analysis: Website based research function using the most important metrics that move share prices.  *** Targeted News: Access to news from small companies releasing significant news.  *** Resources: Learner videos on income statements, balance sheets, cash flow statements and charts plus spreadsheets to help you personally analyse companies.  *** Chat: Access to the Club's chat group.  For more information on the SharePickers Investment Club visit below: https://www.sharepickers.com Twitter @SharePickers https://twitter.com/SharePickers  LinkedIn https://www.linkedin.com/in/justinadamwaite/  NOTHING IN THIS PODCAST IS INVESTMENT ADVICE. PLEASE DO YOUR OWN RESEARCH OR IF YOU ARE UNSURE PLEASE SEEK PROFESSIONAL ADVICE FROM A REGULATED ADVISOR.

Ampersand Biomedicines CEO Jason Gardner, Ph.D. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with the Flagship Pioneering-backed Ampersand, he's putting all those hard-fought lessons to good use. On this episode of the Business of Biotech -- the final (finally!) of several recorded at the JPM Healthcare Conference in January -- Gardner shares how and why he's applying his experience to the buildout of a precision medicine platform company, his thoughts on how big data and AI are influencing the precision medicine space and putting the "tech" in "techbio," his company's acquisition strategy, most recently demonstrated by Ampersand's acquisition of AbCheck, why "paranoid optimism" is central to his company's culture, and much, much more. You've listened along for years -- now you can watch along, too! Go to bioprocessonline.com/solution/the-business-of-biotech-podcast, where you can put faces to voices as you watch hundreds of interviews with the world's best biotech builders. While you're there, subscribe to the #BusinessofBiotech newsletter at bioprocessonline.com/bob for more real, honest, transparent interactions with the leaders of emerging biotech. It's a once-per-month dose of insight and intel that you'll actually look forward to receiving! Check it out at bioprocessonline.com/bob!

As new drugs in development have poorer solubility and bioavailability, there is a need for novel solubility enhancing polymers to improve drug loading and improve patient adherence. In this podcast, Nick DiFranco explains some of the shortcomings of traditional solubility enhancers as well as key considerations for novel technologies. Nick also presents an overview of Lubrizol's Apinovex™ polymers for oral solubility enhancement and Apisolex™ polymers for injectable solubility enhancement.  For more information about Lubrizol Life Science, visit Lubrizol.com.  For more information about the PODD Conference, please visit PODDConference.com.

Today's episode explores the revolutionary landscape of automated drug delivery systems in anesthesia. The hosts unravel the intricacies of these technologies, discussing real-world examples and contemplating the integration of adaptive, intelligent computer systems. So, whether you're a seasoned practitioner or simply curious about the convergence of medicine and technology, this podcast episode serves as an insightful gateway to the forefront of precision anesthesia. Join the conversation and stay informed about the transformative potential of automated drug delivery in anesthesia.   Here's some of what we discuss in this episode: An overview of what we mean by automated drug delivery systems. How is AI influencing how we administer anesthesia, and how does it impact patient outcomes? Controlling the delicate balance between nociception and antinociception poses unique challenges. The sophisticated control methods shaping the future of closed-loop systems.   Visit us online and get show resources here: https://beyondthemaskpodcast.com/   Get the CE Certificate here: https://beyondthemaskpodcast.com/wp-content/uploads/2020/04/Beyond-the-Mask-CE-Cert-FILLABLE.pdf   Help us grow by leaving a review: https://podcasts.apple.com/us/podcast/beyond-the-mask-innovation-opportunities-for-crnas/id1440309246

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. AstraZeneca is making a big move in the cell therapy manufacturing field. The company plans to invest $300 million in a new facility in Rockville, Maryland. This investment comes after AstraZeneca has made several deals in the therapeutic field, showing their commitment to advancing medical treatments. In other news, Kyverna, a developer of cell therapies for autoimmune diseases, has raised an impressive $319 million through its IPO. This makes Kyverna the fifth drug startup to go public in 2024. It's great to see so much interest and support for innovative treatments that can make a difference in patients' lives. Another exciting development is happening at Neurona, which has raised an additional $120 million for its brain disease cell therapies. This signals renewed interest from investors in this area of research, recognizing the potential for breakthrough treatments. It's encouraging to see financial support for advancements in brain disease therapies. We also have Alex Morgan from Khosla Ventures joining us today to discuss the challenges of biotech and the importance of solving drug delivery. It's crucial to find better ways to deliver medications to patients, ensuring their efficacy and safety. We look forward to hearing Alex's insights on this critical topic. Moving on, German biotech company BioNTech has partnered with Autolus to boost cell therapy manufacturing. This collaboration involves a $200 million investment by BioNTech in Autolus, giving them licensing options and access to supply infrastructure. It's great to see companies joining forces to accelerate progress in the field of cell therapy manufacturing. Lastly, Novo Holdings, a subsidiary of Novo Nordisk, has some big plans for expansion. They are set to purchase contract drug manufacturer Catalent for a whopping $16.5 billion. Additionally, Novo Nordisk will acquire three major Catalent factories for $11 billion to meet the increasing demand for their obesity and diabetes medicines. It's clear that Novo Nordisk is committed to ensuring patients have access to the treatments they need. That's all for today's episode of Pharma and Biotech Daily. Stay tuned for more important news and updates in the world of Pharma and Biotech. Have a great day!

Embark on a journey into tomorrow's world with me, Myles Dhillon, as we tackle the evolving landscapes of AI and the job market—debunking the myth of widespread job loss with a dose of reality about cost and complexity. We're also peeling back the curtain on a remarkable innovation from the University of North Carolina: the SOP. It's a wearable, needle-free, smartphone-controlled patch that promises to revolutionize drug delivery for those battling chronic and neurodegenerative conditions, and we're diving into the science that makes it all possible.Prepare to have your mind expanded with a sneak peek into the realm of dream control—an experimental technology being brought to life through the collaborative genius of Profetic and Card 79. I'm trying to secure a spot on the beta list for this dream-designing device and will be bringing you all the vivid details of my personal experiences. This episode promises to be an odyssey of innovation, from the practical to the nearly prophetic, as we explore how these advancements could reshape our daily lives and inner worlds. Hit play and join the exploration of these groundbreaking technologies that are blurring the lines between science fiction and reality.Get intouch with Myles at mylesdhillon@gmail.com

Coss Marte, a native of New York City, went from being a kingpin in criminal activities to serving multiple years in state prison, where he underwent a transformative experience. During his time in prison, he had a profound realization and decided to change his life. Using his prison experience as inspiration, he created the ConBody fitness program, a unique initiative that provides effective workouts and fitness training while offering second chances to formerly incarcerated individuals, helping them reintegrate into society. Additionally, Marte established the ConBud dispensary, likely focusing on legal cannabis products, showcasing his commitment to creating opportunities for those who have faced obstacles in their past. His journey from a life of crime to becoming a fitness innovator and community leader is a powerful testament to redemption and positive transformation. Hosted, Executive Produced & Edited By Ian Bick: https://www.instagram.com/ian_bick/?hl=en https://ianbick.com/ Big thanks to Find A Great Attorney for sponsoring this episode. If you are injured anywhere in the country, visit https://findagreatattorney.com, a free service that can find you one of the best lawyers in your area. You focus on getting better and they'll do the rest. Connect with Coss Marte: IG: https://www.instagram.com/cossmarte/?hl=en Buy Merch: https://lockedinbrand.com Use code lockedin at checkout to get 20% off your order Timestamps: 00:00:00 - Intro 00:04:40 - Growing up in the Neighborhood 00:07:05 - Overcoming Challenges and Changing Narratives 00:11:39 - Growing up in the Dominican Republic 00:16:21 - Rearrested Multiple Times 00:21:00 - The Rise of the Empire 00:28:12 - The Drive for Wealth 00:32:49 - Arrested in the Stash House 00:39:44 - Operating a Business 00:51:33 - Starting a Business 00:56:18 - Working Out in Prison 00:58:30 - Overcoming Doubters and Inspiring Change 01:00:58 - From Advocacy to Working with Mike Tyson 01:03:22 - Carrying the Brand and Overcoming Hurdles 01:07:59 - Advice for Former Prisoners Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Pankaj Karande is an Associate Professor in Chemical and Biological Engineering at Rensselaer Polytechnic Institute. Pankaj was trained as a chemical engineer, and his research aims to apply engineering approaches and technology to solve problems in biology and healthcare to improve the quality and quantity of human life. Projects in his lab span areas such as drug discovery, drug delivery, biomaterials, diagnostics, and more. When he's not working, Pankaj loves to cook, and experimenting with different recipes has been a great way to relieve stress. He was awarded his B.S. in Chemical Engineering from Mumbai University Institute of Chemical Technology and his Ph.D. in Chemical Engineering from the University of California, Santa Barbara. Pankaj was awarded an Anna Fuller Postdoctoral Fellowship in Molecular Oncology, and he conducted postdoctoral research in the Center for Cancer Research at Massachusetts Institute of Technology before joining the faculty at Rensselaer. Pankaj has received a variety of awards and honors in his career, including the Excellence in Classroom Instruction Award and the Outstanding Teaching Award from Rensselaer Polytechnic Institute. He also received the Alzheimer's Association New Investigator Research Award, the Goldhirsh Brain Tumor Research Award, and a Bronze Edison Award in the Best New Product in Science and Medical Category. In addition, he has been issued multiple patents in the areas of Transdermal Formulation Discovery and Novel High Throughput Screening Platforms. In our interview, Pankaj shares more about his life and science.

To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.

To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.

To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.

To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.

To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.

To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.

To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.

To learn more about the PODD: Partnership Opportunities in Drug Delivery Conference, please visit PODDConference.com.

Patients are more likely to adhere to their treatment plans when drug-delivery devices are user-friendly. So, what can device developers do to ensure safety but also provide a positive user experience? Using human factors engineering, developers can design features to prevent errors and contribute to the successful use of the device. On this episode of Here's an Idea™, talking Jeff Morang, Director of Human Factors Engineering at BlackHägen Design, explains what designers need to know about human factors for combination devices.

Paramedics in a rural setting respond to a young man who is unresponsive, barely breathing, has pinpoint pupils and has fresh needle marks along his arm veins. Recognizing this as an opiate overdose they assist ventilations and attempt to administer IV naloxone, but have difficulty starting an IV line. They heard about nasal naloxone, so they squirt a vial of naloxone into the patient's nose with a syringe (1 ml of 0.4 mg). It does not have any effect but they manage to establish an IV and administer another 0.4 mg IV. The patient awakens. Based on this experience, they decide nasal naloxone does not work and resist adoption of the concept during future discussions. Read the full article here.